Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Figure 2 Imaging at diagnosis, after four cycles of chemotherapy with DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase), and 10 mo posttreatment withdeath-ligand 1antibody and chidamide. A: Positron emission tomography showing hypermetabolism in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of the nasopharynx, the bilateral tonsil, and the left preauricular, bilateral neck, and right hilar lymph nodes; B: After four cycles of DDGP chemotherapy, increased metabolism of the lesions was observed except in the right hilar lymph nodes; C: Patient achieved sustained remission for approximately 10 mo.